Other
Federal
Vertex Pharmaceuticals Federal remained flat by 0.0% to $169.78M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 3.7%, from $176.23M to $169.78M. Over 2 years (FY 2023 to FY 2025), Federal shows a downward trend with a -13.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOther
CategoryProfitability
SignalLower is better
VolatilityModerate
First reportedQ1 2023
Last reportedQ4 2025Feb 13, 2026
How to read this metric
Changes reflect fluctuations in taxable income and federal tax rate impacts.
Detailed definition
The portion of the total income tax provision that is payable to the federal government for the current reporting period...
Peer comparison
Standard tax disclosure for all domestic corporations.
Metric ID:
other_current_federal_tax_expense_benefitHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $900.40M | $704.90M | $679.10M |
| YoY Change | — | -21.7% | -3.7% |
Range$679.10M – $900.40M
CAGR-13.2%
Avg YoY Growth-12.7%
Median YoY Growth-12.7%
Current Streak2+ years decline
Federal at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's federal?
- Vertex Pharmaceuticals (VRTX) reported federal of $169.78M in Q4 2025.
- How has Vertex Pharmaceuticals's federal changed year-over-year?
- Vertex Pharmaceuticals's federal decreased by 3.7% year-over-year, from $176.23M to $169.78M.
- What is the long-term trend for Vertex Pharmaceuticals's federal?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's federal has grown at a -13.2% compound annual growth rate (CAGR), from $900.40M to $679.10M.
- What does federal mean?
- Current federal income tax expense for the period.